References
- Stewart A, Cummins C, Gold L, et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG. 2001;108:74–86.
- National Institute for Health and Clinical Excellence. Long-acting reversible contraception. Clinical guideline CG30. London: RCOG; 2005.
- Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97:616–622.e3.
- Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol. 2004;190:50–54.
- Abdel-Aleem H, d'Arcangues C, Vogelsong KM, et al. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev. 2013;10:CD003449.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
- Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration; 2011. https://training.cochrane.org/handbook/
- Mustafa RA, Santesso N, Brozek J, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin Epidemiol. 2013;66:736–742.
- Sterne JAC, Hernán MAH, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
- Cohen MA, Simmons KB, Edelman AB, Jensen JT. Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial. Contraception. 2019;100:391–396.
- Fava M, Peloggia A, Baccaro LF, et al. A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system. Int J Gynaecol Obstet. 2020;149:10–15.
- Lal S, Kriplani A, Kulshrestha V, et al. Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system. Int J Gynaecol Obstet. 2010;109:128–130.
- Madden T, Proehl S, Allsworth JE, et al. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. Am J Obstet Gynecol. 2012;206:129.e1–129.e8.
- Oderkerk TJ, van der Heijden PAHH, Tibosch RMG, et al. Treatment of irregular bleeding with oestradiol during long-term levonorgestrel-releasing intrauterine system (LNG-IUS) use. Front Women’s Health 2019;4:1–3.
- Papaikonomou K, Kopp Kallner H, Söderdahl F, Gemzell-Danielsson K. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control – a randomized controlled trial. Hum Reprod 2018;33:2002–2009.
- Sørdal T, Inki P, Draeby J, et al. Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. J Clin Epidemiol 2013;121:934–941.
- Warner P, Guttinger A, Glasier AF, et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Hum Reprod. 2010;25:345–353.
- Meijer LJ, Bruinsma ACA, Pameijer AS, et al. Dutch College of General Practitioners standard: vaginal bleeding (third revision). Huisarts Wet 2014;57:406–414. [in Dutch]
- Rahn DD, Abed H, Sung VW, et al. Systematic review highlights difficulty interpreting diverse clinical outcomes in abnormal uterine bleeding trials. J Epidemiol 2011;64:293–300.